Comerford E, Norcross L, Sasane M, Zheng Y, Gnanasakthy A. Patient-reported outcome (PRO) data in oncology NDAs approved by the FDA (2018–2021): a review of criticism and concerns in comments from regulators. Poster presented at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference; April 5, 2024. Orlando, FL. [abstract] J Natl Compr Canc Netw. 2024 Apr 5; 22(2.5). doi: 10.6004/jnccn.2023.7146
Wheeler SB, Kohler RE, Reeder-Hayes KE, Goyal RK, Lich KH, Moore A, Smith TW, Melvin CL, Muss HB. Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors. J Cancer Surviv. 2014 Dec;8(4):603-10. doi: 10.1007/s11764-014-0365-3
Chirila C, Odom D, Devercelli G, Khan S, Sherif BN, Kaye JA, Molnar I, Sherrill B. Meta-analysis of the association between progression-free survival and overall survival in metastatic colorectal cancer. Int J Colorectal Dis. 2012 May 1;27(5):623-34.
Odom D, Barber B, Bennett L, Peeters M, Zhao Z, Kaye J, Wolf M, Wiezorek J. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis. 2011 Feb 1;26(2):173-81.
Khalil S, Rodarte A, Weldon BC, Weinstein M, Grunwald Z, Ginsberg B, Kaye R, Otto A, Wheeler M, Lawhorn CD, Prillaman BA, Creed M. Intravenous ondansetron in established postoperative emesis in children. S3A-381 study group. Anesthesiology. 1996 Aug;85(2):270-6. doi: 10.1097/00000542-199608000-00007